$ Value
$4.5M
Shares
2,941,176
Price
$2
Filed
Sep 15
Insider
Name
Schwab Andrew J.
Title
—
CIK
0001598549
Roles
Transaction Details
Transaction Date
2025-09-11
Code
A
Table
Non-Derivative
Ownership
Indirect
Equity Swap
No
Shares After
2,941,176
Footnotes
The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. | The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. The Reporting Person is a managing member of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II GP. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
Filing Info
Schwab Andrew J.'s History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-31 | SKYE | A | $0 |
| 2025-09-11 | CAMP | A | $4.5M |
| 2025-08-22 | SKYE | ▼ | $561K |
| 2025-08-22 | SKYE | ▼ | $22K |
| 2025-08-21 | SKYE | ▼ | $209K |
| 2025-08-21 | SKYE | ▼ | $8K |
| 2025-06-25 | CAMP | A | $0 |
Other Insiders at CAMP (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MacLean Michael F | — | — | 2026-04-01 |
|
Maricich Yuri
Chief Medical Officer
|
— | — | 2026-04-01 |
|
Mandel-Brehm Josh
Chief Executive Officer
|
— | — | 2026-04-01 |
|
Gold Kelly
Chief Financial Officer
|
— | — | 2026-04-01 |
|
Tardiff Daniel
Chief Scientific Officer
|
— | — | 2026-04-01 |